SCHEMBL4407657

SCHEMBL4407657

CCN1C(=O)N(c2c(Cl)cc(F)c(O)c2F)Cc2cnc(NCCCCCN3CCN(C)CC3)nc21

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 19/20 0.43
SRC P12931 6/20 0.43
EGFR P00533 4/20 0.43
FGFR2 P21802 4/20 0.39
FGFR4 P22455 4/20 0.39
FGFR3 P22607 4/20 0.39
MAPK8 P45983 1/20 0.37
PRKD3 O94806 1/20 0.35
PRKCG P05129 1/20 0.35
PRKCB P05771 1/20 0.35
PRKCA P17252 1/20 0.35
PRKCH P24723 1/20 0.35
PRKCI P41743 1/20 0.35
PRKCE Q02156 1/20 0.35
PRKCQ Q04759 1/20 0.35
PRKCZ Q05513 1/20 0.35
PRKCD Q05655 1/20 0.35
PRKD1 Q15139 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411904 0.88 FGFR1 (0.44) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4398321 0.87 FGFR1 (0.51) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4541163 0.87 FGFR1 (0.43) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4408039 0.87 FGFR4 (0.42) FGFR1FGFR2FGFR4FGFR3
SCHEMBL4397720 0.85 FGFR1 (0.40) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4412250 0.84 FGFR4 (0.43) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4403252 0.84 FGFR1 (0.42) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4404693 0.84 FGFR4 (0.47) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4395810 0.84 FGFR4 (0.42) FGFR1SRCEGFRFGFR2FGFR4
SCHEMBL4405661 0.83 FGFR1 (0.50) FGFR1FGFR2FGFR4FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549651-B1 PYRIMIDOPYRIMIDONES AS KINASE INHIBITORS WARNER LAMBERT CO (US) 2009-12-23 EP disclosed
US-7196090-B2 Kinase inhibitors WARNER-LAMBERT COMPANY (US) 2007-03-27 US disclosed
WO-2006038112-A1 USE OF KINASE INHIBITORS TO PROMOTE NEOCHONDROGENESIS WARNER-LAMBERT COMPANY LLC (US) 2006-04-13 WO disclosed
EP-1549651-A1 KINASE INHIBITORS Warner-Lambert Company LLC (US) 2005-07-06 EP disclosed
WO-2004011465-A1 KINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-05 WO disclosed
US-20040019210-A1 Kinase inhibitors CHIVIKAS CONNOLLY CLEO J (US) 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040019210-A1 Kinase inhibitors CDK2, CDK1, CDK4 FGFR1 88/4885SRC 223/4885EGFR 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.